The Additional Hetero Ring Is Five-membered Consisting Of One Nitrogen And Four Carbons Patents (Class 546/276.4)
  • Patent number: 7247735
    Abstract: In the case of the materials according to the invention, the charge carrier mobility in the correspondingly prepared films is achieved if the molecules are composed in such a way that side chains—consisting of conjugated aromatic or heteroaromatic systems—are attached in direct conjugation to a central aromatic or heteroaromatic ring so that the total molecule acquires an octupolar structure. This octupolar structure permits an effective ?-? interaction of the molecules with one another in a manner such that stacking of a plurality of molecules along an imaginary axis (central ring) can take place and various stacks from among these stacks can interact with one another by intermeshing of the side chains. The electronic properties of the materials are determined both by the arrangement of the molecules in a layer and by the molecular design.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: July 24, 2007
    Assignee: Infineon Technologies AG
    Inventors: Marcus Halik, Hagen Klauk, Guenter Schmid
  • Patent number: 7247648
    Abstract: Compounds of Formula (I) are effective in the treatment of a microbial infection.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: July 24, 2007
    Assignee: The Procter & Gamble Company
    Inventors: Namal Chithranga Warshokoon, Rodney Dean Bush
  • Patent number: 7241745
    Abstract: The invention relates to a new pyridyl alkene and pyridyl alkine acid amides according to the general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: July 10, 2007
    Assignee: Astellas Pharma GmbH
    Inventors: Elfi Biedermann, Max Hasmann, Roland Löser, Benno Rattel, Friedemann Reiter, Barbara Schein, Klaus Seibel, Klaus Vogt
  • Patent number: 7235566
    Abstract: Compounds of formula (I): are inhibitors of the enzyme Lp-PLA2 and are of use in therapy, in particular for treating atherosclerosis.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: June 26, 2007
    Assignee: Smithkline Beecham p.l.c.
    Inventors: Deirdre Mary Bernadette Hickey, Robert John Ife, Colin Andrew Leach, John Liddle, Ivan Leo Pinto, Stephen Allan Smith, Steven James Stanway
  • Patent number: 7220761
    Abstract: The present invention includes compounds of pyridinium salts and methods of their use for industrial uses. The present invention also relates to methods of controlling fungi and/or bacteria. The present invention may also be used to control insects.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: May 22, 2007
    Assignee: Mycosol, Inc.
    Inventors: Richard B. Klein, Jeffrey L. Selph, John J. Partridge, John Reinhard
  • Patent number: 7214678
    Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: May 8, 2007
    Assignee: Allergan, Inc.
    Inventors: Robert M. Burk, Sophie Beauchemin
  • Patent number: 7205305
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: April 17, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy W Bemis, Francesco G Salituro, John P Duffy, John E Cochran, Edmund M Harrington, Mark A Murcko, Keith P Wilson, Michael Su, Vincent P Galullo
  • Patent number: 7189755
    Abstract: Melanocortin receptor-specific pyrrolidine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: March 13, 2007
    Assignee: Palatin Technologies, Inc.
    Inventors: Shubh D. Sharma, Yi-Qun Shi, Zhijun Wu, Ramesh Rajpurohit
  • Patent number: 7186722
    Abstract: Novel ?1-pyrrolines of the Formula (I) in which R1, R2, R3 and Het have the meanings given in the description, a plurality of processes for preparing these compounds and their use for controlling pests, and also novel intermediates and processes for their preparation.
    Type: Grant
    Filed: January 31, 2002
    Date of Patent: March 6, 2007
    Assignee: Bayer Cropscience AG
    Inventors: Andrew Plant, Rüdiger Fischer, Thomas Seitz, Christoph Erdelen, Andreas Turberg, Olaf Hansen
  • Patent number: 7186843
    Abstract: This invention provides a quinolone derivative having potent antibacterial activity against various bacteria including drug-resistant strains which is a compound of the following formula wherein R1 is an optionally substituted aromatic group, a salt of the same or a hydrate of both.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: March 6, 2007
    Assignee: Daiichi Pharmaceutical Co. Ltd.
    Inventors: Makoto Takemura, Hisashi Takahashi, Katsuhiro Kawakami, Toshiyuki Takeda, Rie Miyauchi
  • Patent number: 7183297
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: February 27, 2007
    Assignee: Glaxo Group Limited
    Inventors: Richard Martyn Angell, Nicola Mary Aston, Paul Bamborough, Mark James Bamford, George Stuart Cockerill, Stephen Sean Flack, Dramane Ibrahim Lainé, Ann Louise Walker
  • Patent number: 7179806
    Abstract: The invention relates to novel ?1-pyrrolines of the formula (I) in which R1, R2, R3, m, and Q have the meanings given in the disclosure, to a plurality of processes for preparing these substances, and to their use for controlling pests.
    Type: Grant
    Filed: November 22, 2001
    Date of Patent: February 20, 2007
    Assignee: Bayer Cropscience AG
    Inventors: Andrew Plant, Thomas Seitz, Johannes Rudolf Jansen, Christoph Erdelen, Andreas Turberg, Olaf Hansen
  • Patent number: 7173129
    Abstract: The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: February 6, 2007
    Assignee: Athero Genics, Inc.
    Inventors: Kimberly J. Worsencroft, Liming Ni, Zhihong Ye, Charles Q. Meng, M. David Weingarten, Jacob E. Simpson, James A. Sikorski
  • Patent number: 7169779
    Abstract: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: January 30, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francesco Salituro, Guy Bemis, Huai Gao, Ghotas Evindar
  • Patent number: 7166637
    Abstract: The invention relates to substituted 4- or/and 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 4 activity in immunocompetent cells (e.g. macrophages and lymphocytes).
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: January 23, 2007
    Assignee: Elbion AG
    Inventors: Norbert Höfgen, Hildegard Kuss, Ute Egerland, Chris Rundfeldt, Helge Hartenhauer, Antje Gasparic
  • Patent number: 7138416
    Abstract: The invention discloses a novel series of compound represented by general formula (I), its derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, pharmaceutically acceptable salts, and solvates wherein X, n, k, z, R1, R2, R3, R4, R5 and R6 are as defined in the specification that are useful in (i) normalizing elevated blood glucose levels in diabetics, (ii) treating disorders related to glucose intolerance and (iii) for scavenging free radicals in mammals.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: November 21, 2006
    Assignee: Torrent Pharmaceuticals Ltd.
    Inventor: Alangudi Sankaranarayanan
  • Patent number: 7138376
    Abstract: A compound, method and composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4?-disubstituted nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: November 21, 2006
    Assignees: Idenix Pharmaceuticals, Inc., Centre National de la Recherche Scientifique
    Inventors: Gilles Gosselin, Jean-Louis Imbach, Jean-Pierre Sommadossi
  • Patent number: 7135472
    Abstract: The present invention provides novel 3-heterocyclic benzylamides and related derivatives having the general Formula I wherein R1, R2, R3, R4, R5, R6, A and Het are as defined in the specification, or a nontoxic pharmaceutically acceptable salt, solvate or hydrate thereof which are openers or activators of KCNQ potassium channels. The present invention also provides pharmaceutical compositions comprising said novel 3-heterocyclic benzylamides and to the method of treatment of disorders sensitive to KCNQ potassium channel opening activity such as migraine or a migraine attack, bipolar disorders, epilepsy, acute and chronic pain and anxiety.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: November 14, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yong-Jin Wu, Alexandre L'Heureux, Huan He
  • Patent number: 7132543
    Abstract: The present disclosure relates to a novel a para-phenylenediamine derivative substituted with a pyrrolidinyl group of formula (I) and the addition salts thereof. The present disclosure also relates to a dyeing composition for keratin fibers comprising the paraphenylene derivative as at least one oxidation base, and to a process for dyeing keratin fibers and a multi-compartment kit using the claimed dye composition. Such a composition makes it possible to obtain a chromatic, powerful, unselective and fast coloration of keratin fibers.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: November 7, 2006
    Assignee: L'Oreal S.A.
    Inventors: Laure Ramos, Stéphane Sabelle
  • Patent number: 7132545
    Abstract: Methods of synthesizing nicotine analogs and derivatives are described. In some embodiments the methods utilize an alkyl or aryl silyl-substituted nicotine analog intermediate. Intermediates useful for the synthesis of nicotine and nicotine analogs are also described.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: November 7, 2006
    Assignee: North Carolina State University
    Inventors: Daniel L. Comins, Emilie Despagnet Smith
  • Patent number: 7125887
    Abstract: Pyrrolidine compounds of Formula (I), (wherein R1, R2, R3, R4, R5, R6a, R6b, R7 and R8 are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: October 24, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey J. Hale, Charles G. Caldwell, Dooseop Kim, Dong-Ming Shen, Sander G. Mills, Kevin T. Chapman, Liya Chen, Malcolm MacCoss, Amy Gentry, Christopher L. Lynch, Yuan Cheng, legal representative, Christopher A. Willoughby, deceased
  • Patent number: 7125878
    Abstract: The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: October 24, 2006
    Assignee: Janssen Pharmaceutica
    Inventors: Han-Cheng Zhang, Gee-Hong Kuo, Bruce E. Maryanoff, Hong Ye, David O'Neill, Lan Shen, Keith Demarest, Bruce R. Conway, David F. McComsey
  • Patent number: 7122666
    Abstract: Compounds having activity against production of an inflammatory cytokine of formula (I)?: A? is pyrrole; R1? is phenyl or naphthyl; R2? is pyridyl or pyrimidinyl; R3? is (IIa)?, (IIb)? or (IIc)?: m? is 1; E? is nitrogen; D? is >C(R5?)—, R5? is hydrogen, Substituent ?? or Substituent ??; B? is nitrogen-containing 5-membered heterocyclic; R4? is 1 to 3 substituents from Substituent ??, Substituent ?? and Substituent ??; R1? and R3? are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R2?; Substituent ?? is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NRa?Rb?; Ra? and Rb? are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or Ra? and Rb? with the nitrogen atom form a heterocyclyl; Substituent ?? is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent ?? is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: October 17, 2006
    Assignee: Sankyo Company, Limited
    Inventors: Tomio Kimura, Akira Nakao, Nobuyuki Ohkawa, Takayoshi Nagasaki, Takanori Yamazaki
  • Patent number: 7115603
    Abstract: This invention relates to novel ?1-pyrrolines of formula(I) in which R1, R2, Y and R3 are as defined in the disclosure, to a number of processes for preparing these substances, and to their use for controlling pests.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: October 3, 2006
    Assignee: Bayer CropScience AG
    Inventors: Thomas Seitz, Martin Füsslein, Johannes-Rudolf Jansen, Udo Kraatz, Angelika Lubos-Erdelen, legal representative, Andreas Turberg, Olaf Hansen, Christoph Erdelen, deceased
  • Patent number: 7105556
    Abstract: Compounds are provided which have the structure wherein Q is C or N, X1 is C or N, and R1, R2, R2a, R2b, R2c, R3, Y, A, m, n, X2, X3 and X4 are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: September 12, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter T. Cheng, Yoon Jeon, Wei Wang
  • Patent number: 7105537
    Abstract: The present invention relates to modulators of the calcium sensing receptor having the formula I wherein Ar1, X, n, R1, R2, R3 and Q are as defined herein.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: September 12, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ashvinikumar V. Gavai, Roy J. Vaz, John K. Dickson, Jr., Jacques Y. Roberge, Wu Yang, Timur Gungor, James R. Corte, David P. Rotella, Yufeng Wang
  • Patent number: 7101896
    Abstract: The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacyclic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetylenic cycloalkylamines. The present invention also relates to prodrug derivatives of the compounds of the present invention.
    Type: Grant
    Filed: January 20, 2005
    Date of Patent: September 5, 2006
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Craig Harrison Miller
  • Patent number: 7091204
    Abstract: The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: August 15, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Dashyant Dhanak, Timothy F. Gallagher, Steven D. Knight
  • Patent number: 7074785
    Abstract: Novel ?1-pyrrolines of the formula (I) in which R1, R2, R3, A, R4 and m have the meanings given in the description, a number of processes for preparing these substances, and their use for controlling pests, and also novel intermediates and their preparation.
    Type: Grant
    Filed: September 4, 2002
    Date of Patent: July 11, 2006
    Assignee: Bayer Cropscience AG
    Inventors: Thomas Seitz, Martin Füsslein, Johannes Rudolf Jansen, Udo Kraatz, Angelika Lubos-Erdelen, legal representative, Andreas Turberg, Olaf Hansen, Christoph Erdelen, deceased
  • Patent number: 7067672
    Abstract: A first aspect of the present invention is a method for of making a compound of Formula Ia or Formula Ib: wherein X is halo, by (a) metalating a precursor compound to form an organometallic intermediate, and then reacting the organometallic intermediate with a halogenating agent to produce the compound of Formula Ia or Formula Ib.
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: June 27, 2006
    Assignee: North Carolina State University
    Inventors: Daniel L. Comins, Florence Fevrier, Emilie Despagnet Smith
  • Patent number: 7064124
    Abstract: A NF-?B inhibitor represented by the following formula (I) is provided: ?
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: June 20, 2006
    Assignees: Daiichi Suntory Pharma Co., Ltd., Daiichi Suntory Biomedical Research Co., Ltd.
    Inventors: Kenji Suzuki, Yoichi Nunokawa, Naohisa Ogou
  • Patent number: 7049442
    Abstract: Mixed bis-imine pyridine ligands of formula (I), wherein Z1, which is different from Z2, is an optionally substituted aryl group; and Z2 comprises an optionally substituted heterohydrocarbyl moiety, or an optionally substituted aryl group in combination with a metal, said optionally substituted aryl group being ?-co-ordinated to the metal; mixed bis-imine pyridine complexes comprising a ligand of formula (I); mixed ionic bis-imine pyridine complexes comprising a ligand of formula (I); and processes for the production of alpha olefins from ethylene, using said complexes.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: May 23, 2006
    Assignee: Shell Oil Company
    Inventors: Eric Johannes Maria De Boer, Harry Van Der Heijden, Wihelmina Cornelia Verhoef-Van Wijk, Arie Van Zon
  • Patent number: 7037880
    Abstract: Ethylene derivatives of formula (I): where Q is an unsubstituted or substituted phenyl or heterocyclic group, especially a 4-thiazolyl, 1- or 3-pyrazolyl, 1,3-oxazol-4-yl, phenyl or pyridyl group; E is a substituent such as a cyano group; A is a substituent such as a 4-pyrazolyl or thiazolyl group; and B is a substituent such as an alkylcarbonyl group. Agricultural chemicals and agents for preventing the attachment of aquatic organisms containing one or more such ethylene derivatives.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: May 2, 2006
    Assignee: Nissan Chemical Industries, Ltd.
    Inventors: Tomoyuki Ogura, Hiroshi Murakami, Akira Numata, Rika Miyachi, Toshiro Miyake, Norihiko Mimori, Shinji Takii
  • Patent number: 7022695
    Abstract: Thioether-substituted benzamide compounds having the formula: are provided that exhibit exceptionally strong inhibition of Factor Xa in combination with weak hERG binding.
    Type: Grant
    Filed: October 5, 2004
    Date of Patent: April 4, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Erick A. Goldman, Wenrong Huang, Penglie Zhang
  • Patent number: 7012085
    Abstract: The invention provides compounds of formula (I) wherein R0, R1, R2 and A are as defined in the description, and the preparation thereof. The compounds of formula (I) have high affinity as ?2 adrenoceptors and hence are useful as pharmaceuticals.
    Type: Grant
    Filed: January 26, 2001
    Date of Patent: March 14, 2006
    Assignee: Novartis AG
    Inventors: Max Peter Seiler, Joachim Nozulak
  • Patent number: 6995265
    Abstract: Methods of synthesizing nicotine analogs and derivatives are described. In some embodiments the methods utilize an alkyl or aryl silyl-substituted nicotine analog intermediate. Intermediates useful for the synthesis of nicotine and nicotine analogs are also described.
    Type: Grant
    Filed: August 25, 2004
    Date of Patent: February 7, 2006
    Assignee: North Carolina State University
    Inventors: Daniel L. Comins, Emilie Despagnet Smith
  • Patent number: 6984651
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: January 10, 2006
    Assignee: Bristol-Myers Squibb Pharma, Company
    Inventors: John V. Duncia, Joseph B. Santella, Dean A. Wacker, Wenqing Yao, Changsheng Zheng
  • Patent number: 6962941
    Abstract: The compounds of formula I in which M, B1, B2, R1, R2, R6, R7, K1 and K2 have the meanings as indicated in the description are novel active tryptase inhibitors.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: November 8, 2005
    Assignee: Altana Pharma AG
    Inventors: Thomas Martin, Wolf-Rüdiger Ulrich
  • Patent number: 6953807
    Abstract: Compound of general formula (I) in which Y is chosen from the following groups Y1 to Y3 (I*), the other substituents being as defined in the description, process for preparing this compound, fungicidal composition comprising this compound, method for treating plants by applying this compound or composition.
    Type: Grant
    Filed: July 5, 2002
    Date of Patent: October 11, 2005
    Assignee: Bayer Cropscience S.A.
    Inventors: Pierre Hutin, Benoît Muller, Christopher Richard Steele, Joseph Perez, Pierre Genix
  • Patent number: 6949539
    Abstract: The invention provides compounds of general formula (I) in which m, A, R1 and Ar have the meanings defined in the specification; a process for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: September 27, 2005
    Assignee: AstraZeneca AB
    Inventors: Lilian Alcaraz, Mark Furber
  • Patent number: 6949546
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: September 27, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, James R. Pruitt, Dean A. Wacker, Douglas G. Batt
  • Patent number: 6919368
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: February 6, 2003
    Date of Patent: July 19, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, George V. Delucca, John V. Duncia, Ui Tae Kim, Dean A. Wacker, Changsheng Zheng
  • Patent number: 6916933
    Abstract: Compounds of Formula I have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4 and are useful for treating disease whose symptoms and or damage are related to the binding of VCAM-1 to cells expressing VLA-4.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: July 12, 2005
    Assignee: Hoffman-La Roche Inc.
    Inventors: Gerald Lewis Kaplan, Achyutharao Sidduri, Jefferson Wright Tilley
  • Patent number: 6908935
    Abstract: The compounds of the invention are represented by the following general structure or a pharmaceutically acceptable salt thereof, and compositions containing them, wherein the variables are defined herein, and their use to reduce or inhibit PTH secretion, including methods for reducing or inhibiting PTH secretion and methods for treatment or prophylaxis of diseases associated with bone disorders, such as osteoporosis, or associated with excessive secretion of PTH, such as hyperparathyroidism. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: June 21, 2005
    Assignee: Amgen Inc.
    Inventors: Michael G. Kelly, Shimin Xu, Ning Xi, Philip Miller, John F. Kincaid, Chiara Ghiron, Thomas Coulter
  • Patent number: 6903218
    Abstract: This invention related to novel sulfonamide substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: June 7, 2005
    Assignee: Bayer Pharmaceuticals Corporation
    Inventors: Gaetan H. Ladouceur, Richard D. Connell, Jeremy Baryza, Ann-Marie Campbell, Timothy G. Lease, James H. Cook
  • Patent number: 6903132
    Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: June 7, 2005
    Assignees: Agouron Pharmaceuticals, Inc., Pfizer Inc.
    Inventors: Mark B. Anderson, Lance Christopher Christie, Quyen-Quyen Thuy Do, Jun Feng, Yufeng Hong, Haitao Li, Ved P. Pathak, Ranjan Jagath Rajapakse, Eric T. Sun, Eileen Valenzuela Tompkins
  • Patent number: 6897234
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: May 24, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo Ko, George DeLucca, John Duncia, Ui Tae Kim, Joseph B. Santella III, Dean A. Wacker
  • Patent number: 6890935
    Abstract: The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacyclic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetylenic cycloalkylamines. The present invention also relates to prodrug derivatives of the compounds of the present invention.
    Type: Grant
    Filed: April 30, 2001
    Date of Patent: May 10, 2005
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Craig Harrison Miller
  • Patent number: 6875776
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: April 5, 2005
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Soo S. Ko, Cheryl McArdle Clark, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker
  • Patent number: 6858740
    Abstract: The invention concerns 2-oxo-1-pyrrolidine derivatives and a process for preparing them and their uses. The invention also concerns a process for preparing ?-ethyl-2-oxo-1-pyrrolidine acetamide derivatives from unsaturated 2-oxo-1-pyrrolidine derivatives. Particularly the invention concerns novel intermediates and their use in methods for the preparation of S-?-ethyl-2-oxo-1-pyrrolidine acetamide.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: February 22, 2005
    Assignee: UCB Farchim S.A.
    Inventors: John Surtees, Violeta Marmon, Edmond Differding, Vincent Zimmermann